234 related articles for article (PubMed ID: 23901022)
1. Genetic factors and pathogenesis of Waldenström's macroglobulinemia.
Monge J; Braggio E; Ansell SM
Curr Oncol Rep; 2013 Oct; 15(5):450-6. PubMed ID: 23901022
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in Waldenström's macroglobulinemia.
Sacco A; Ghobrial IM; Roccaro AM
Epigenomics; 2010 Oct; 2(5):691-6. PubMed ID: 22122052
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of Waldenstrom's macroglobulinemia.
Braggio E; Philipsborn C; Novak A; Hodge L; Ansell S; Fonseca R
Haematologica; 2012 Sep; 97(9):1281-90. PubMed ID: 22773606
[TBL] [Abstract][Full Text] [Related]
4. High-throughput genomic analysis in Waldenström's macroglobulinemia.
Poulain S; Braggio E; Roumier C; Aijjou R; Broucqsault N; Galiègue-Zouitina S; Manier S; Soenen V; Nibourel O; Duthilleul P; Fonseca R; Leleu X
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):106-8. PubMed ID: 21454205
[TBL] [Abstract][Full Text] [Related]
5. The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.
Sacco A; Fenotti A; Affò L; Bazzana S; Russo D; Presta M; Malagola M; Anastasia A; Motta M; Patterson CJ; Rossi G; Imberti L; Treon SP; Ghobrial IM; Roccaro AM
Oncotarget; 2017 May; 8(21):35435-35444. PubMed ID: 28423722
[TBL] [Abstract][Full Text] [Related]
6. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis.
Sacco A; Maiso P; Azab A; Azab F; Zhang Y; Liu Y; Ngo HT; Morgan B; Quang P; Issa G; Ghobrial IM; Roccaro AM
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):109-11. PubMed ID: 21454206
[TBL] [Abstract][Full Text] [Related]
7. Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.
Kapoor P; Ansell SM; Braggio E
Cancer Treat Res; 2016; 169():321-361. PubMed ID: 27696269
[TBL] [Abstract][Full Text] [Related]
8. Epigenomics in Waldenstrom's macroglobulinaemia.
Sacco A; Fenotti A; Bazzana S; Imberti L; Rossi G; Patterson CJ; Treon SP; Ghobrial IM; Roccaro AM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):156-160. PubMed ID: 27825461
[TBL] [Abstract][Full Text] [Related]
9. [New developments in Waldenström's macroglobulinemia].
Grunenberg A; Buske C
Dtsch Med Wochenschr; 2016 Feb; 141(3):170-2. PubMed ID: 26841176
[TBL] [Abstract][Full Text] [Related]
10. High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.
Braggio E; Keats JJ; Leleu X; Wier SV; Jimenez-Zepeda VH; Schop RF; Chesi M; Barrett M; Stewart AK; Dogan A; Bergsagel PL; Ghobrial IM; Fonseca R
Clin Lymphoma Myeloma; 2009 Mar; 9(1):39-42. PubMed ID: 19362969
[TBL] [Abstract][Full Text] [Related]
11. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
12. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
13. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.
Braggio E; Keats JJ; Leleu X; Van Wier S; Jimenez-Zepeda VH; Valdez R; Schop RF; Price-Troska T; Henderson K; Sacco A; Azab F; Greipp P; Gertz M; Hayman S; Rajkumar SV; Carpten J; Chesi M; Barrett M; Stewart AK; Dogan A; Bergsagel PL; Ghobrial IM; Fonseca R
Cancer Res; 2009 Apr; 69(8):3579-88. PubMed ID: 19351844
[TBL] [Abstract][Full Text] [Related]
14. How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy Strategy.
Baron M; Simon L; Poulain S; Leblond V
Curr Oncol Rep; 2019 Feb; 21(3):27. PubMed ID: 30806816
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
Mailankody S; Landgren O
Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology.
Sacco A; Issa GC; Zhang Y; Liu Y; Maiso P; Ghobrial IM; Roccaro AM
J Hematol Oncol; 2010 Oct; 3():38. PubMed ID: 20929526
[TBL] [Abstract][Full Text] [Related]
17. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
[TBL] [Abstract][Full Text] [Related]
18. Preclinical models of Waldenström's macroglobulinemia and drug resistance.
Ailawadhi S; Paulus A; Chanan-Khan A
Best Pract Res Clin Haematol; 2016 Jun; 29(2):169-178. PubMed ID: 27825463
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X
Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Nguyen-Khac F; Lambert J; Chapiro E; Grelier A; Mould S; Barin C; Daudignon A; Gachard N; Struski S; Henry C; Penther D; Mossafa H; Andrieux J; Eclache V; Bilhou-Nabera C; Luquet I; Terre C; Baranger L; Mugneret F; Chiesa J; Mozziconacci MJ; Callet-Bauchu E; Veronese L; Blons H; Owen R; Lejeune J; Chevret S; Merle-Beral H; Leblondon V; ; ;
Haematologica; 2013 Apr; 98(4):649-54. PubMed ID: 23065509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
